New medical device received therapeutic goods administration (TGA) approval and promises to revoluti
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide and the sole distribution partner outside North America for the new PrecisionPoint™ Transperineal Access System, announces its availability to the Australian healthcare market. The new medical device, which has recently received TGA approval, offers urologists a safer and more accurate method to diagnose potential incidents of prostate cancer.
Developed in response to the increased adoption of active surveillance and the disadvantages in transrectal biopsy approaches, PrecisionPoint™, which has been developed and patented by the US based company Perineologic, is the first TGA approved device that allows a free-handed transperineal systematic or targeted biopsy of the prostate. Removing the requirement for a stabilisation unit and disposable grid. The low-cost, disposable device represents a new approach to prostate cancer detection at an earlier stage of progression, through its ability to allow access to the whole prostate gland.
Saheed Rashid, Managing Director, BXTAccelyon, comments: “Earlier detection of prostate cancer is proven to widen the available treatment options to patients, which will improve outcomes whilst reducing potential adverse side-effects and / or relapse. BXTAccelyon is therefore proud to be the sole distributor for this advanced new methodology.”
The PrecisionPoint™ system takes full advantage of the transperineal path to more thoroughly sample all regions of the prostate including those difficult to access with the traditional transrectal approach. In addition, the potential for infection is significantly reduced, since passage of the biopsy needle avoids the rectal wall contaminants entirely. Equally important, biopsies can be performed under local anaesthesia rather than a general anaesthetic, which saves resources, cost and significantly improves the overall patient experience. This opens up the opportunity of taking transperineal biopsies out of theatre and into a clinic setting.
Dr. Matthew Allaway, CEO, Perineologic, adds: “As an organisation, we are strong advocates of an integrated approach to improve the safety, precision, and efficiency of treatment options for urological disorders, including prostate cancer. These are values which are also closely mirrored by the team at BXTAccelyon; their approach of educating healthcare professionals and patients alike to the benefits and likely outcomes of all treatment options is one we welcome. We are pleased to partner with BXTAccelyon with the aim of improving the overall patient experience and delivering the best possible health outcomes.”